| __timestamp | Amphastar Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 9804000 |
| Thursday, January 1, 2015 | 37065000 | 12796000 |
| Friday, January 1, 2016 | 41199000 | 15324000 |
| Sunday, January 1, 2017 | 43415000 | 13881000 |
| Monday, January 1, 2018 | 57564000 | 14820000 |
| Tuesday, January 1, 2019 | 68853000 | 14851000 |
| Wednesday, January 1, 2020 | 67229000 | 17204000 |
| Friday, January 1, 2021 | 60932000 | 29843000 |
| Saturday, January 1, 2022 | 74771000 | 40603000 |
| Sunday, January 1, 2023 | 73741000 | 57305000 |
Unleashing the power of data
In the competitive landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and Veracyte, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Amphastar Pharmaceuticals consistently increased its R&D spending, peaking in 2022 with a 163% rise from its 2014 levels. This steady growth underscores Amphastar's dedication to expanding its research capabilities. Meanwhile, Veracyte, Inc. exhibited a more dramatic surge, particularly from 2021 onwards, culminating in a 484% increase by 2023 compared to 2014. This leap highlights Veracyte's aggressive push towards innovation in recent years.
These trends not only reflect the companies' strategic priorities but also offer insights into the evolving dynamics of the biotech and pharmaceutical sectors.
Eli Lilly and Company vs Veracyte, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Eli Lilly and Company vs Amphastar Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Novartis AG and Veracyte, Inc.
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Veracyte, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Veracyte, Inc.
R&D Spending Showdown: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc.
Apellis Pharmaceuticals, Inc. vs Veracyte, Inc.: Strategic Focus on R&D Spending
Supernus Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Amphastar Pharmaceuticals, Inc. vs Galapagos NV
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.